甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果评价

Clinical effect evaluation of Apatinib Mesylate Tablets in the treatment of advanced non-small cell lung cancer

目的研究甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果。方法选取2015年1月~2016年8月我院收治的84例晚期非小细胞肺癌患者作为研究对象,随机分为研究组和常规化疗组,各42例。常规化疗组采用常规化疗方案,研究组在常规化疗组的基础上给予甲磺酸阿帕替尼片治疗。比较两组的总缓解率、治疗期间不良反应发生率以及治疗前后生活质量、卡氏评分。结果研究组的总缓解率高于常规化疗组,差异有统计学意义(P<0.05)。研究组治疗后的生活质量、卡氏评分高于对照组治疗后,差异有统计学意义(P<0.05)。研究组治疗期间的不良反应发生率低于常规化疗组,差异有统计学意义(P<0.05)。结论甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果确切,可有效改善患者的临床症状和生活质量,且可减少常规化疗出现的副作用,安全有效,值得推广。

Objective To study the clinical effect of Apatinib Mesylate Tablets in the treatment of advanced non-small cell lung cancer.Methods 84 patients with non-small cell lung cancer in our hospital from January 2015 to August 2016 were selected and randomly divided into the study group and the routine chemotherapy group,42 cases in each group.The routine chemotherapy group was given routine chemotherapy regimen,the study group was given Apatinib Mesylate Tablets on the basis of the routine chemotherapy group.The total remission rate,the incidence rate of adverse reaction and the score of quality of life and the Cartesian score before and after treatment were compared between the two groups.Results The remission rate of the study group was higher than that of the routine chemotherapy group,with significant diference （P〈0.05）.The score of quality of life and the Cartesian score after treatment in the study group was higher than that of the routine chemotherapy group,with significant diference （P〈0.05）.The incidence rate of adverse re- actions in the study group was lower than that of the routine chemotherapy group,with significant diference （P〈0.05）. Conclusion The clinical effect of Apatinib Mesylate Tablets in the treatment of advanced non-small cell lung cancer is exact,which can effectively improve the clinical symptoms and quality of life,and reduce the side effects of conventional chemotherapy,safe and effective,it is worthy of promotion.